Viking Therapeutics, Inc. (VKTX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Viking Therapeutics, Inc. (“Viking” or the “Company”) (NASDAQ: VKTX). Investors who purchased Viking shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Viking and certain of its officers and/or directors have violated federal securities laws.
On January 24, 2022, Viking filed a press release “announc[ing] that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the United States Food and Drug Administration (FDA)” and that “[t]he FDA has requested an additional preclinical study prior to continuing the Phase 1b study of VK0214 in X-ALD.” Viking further stated that it “expects to provide the information to the FDA in the second quarter.” On this news, Viking’s stock price fell $0.25 per share, or 6.56%, to close at $3.56 per share on January 24, 2022.
If you are aware of any facts relating to this investigation or purchased Viking shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.